[EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
申请人:UNIV HEALTH NETWORK
公开号:WO2011123937A1
公开(公告)日:2011-10-13
The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.
[EN] NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME BLOQUEURS DES CANAUX CALCIQUES
申请人:ABBOTT LAB
公开号:WO2010039947A1
公开(公告)日:2010-04-08
The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
[EN] 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 5-FLUORONICOTINAMIDE ET LEURS UTILISATIONS
申请人:TENAYA THERAPEUTICS INC
公开号:WO2021067859A1
公开(公告)日:2021-04-08
Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of heart disease.
[EN] AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZIN-3(2H)-ONE FUSIONNÉS PAR UN AZOLE
申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2021055326A1
公开(公告)日:2021-03-25
Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.